N8 Medical

N8 Medical has developed a proprietary antimicrobial surface-protection platform called CeraShield™, utilizing small molecule mimics of antimicrobial peptides known as ceragenins. Their flagship product, the CeraShield-coated endotracheal tube, has shown promising early clinical results in reducing bacterial and fungal colonization and biofilm formation—key drivers of ventilator-associated pneumonia and other hospital-acquired infections. The company’s approach aims to reduce infection rates, antibiotic use, and ICU stays. The FDA designated the lead device a "breakthrough device," reflecting its potential impact on patient outcomes. Early human studies have demonstrated safety and efficacy signals.